Abstract
Comprehensive analysis of the clonotypic B cell receptor immunoglobulin (BcR IG) gene rearrangement sequences in patients with mature B cell neoplasms has led to the identification of significant repertoire restrictions, culminating in the discovery of subsets of patients expressing highly similar, stereotyped BcR IG. This finding strongly supports selection by common epitopes or classes of structurally similar epitopes in the ontogeny of these tumors. BcR IG stereotypy was initially described in chronic lymphocytic leukemia (CLL), where the stereotyped fraction of the disease accounts for a remarkable one-third of patients. However, subsequent studies showed that stereotyped BcR IG are also present in other neoplasms of mature B cells, including mantle cell lymphoma (MCL) and splenic marginal zone lymphoma (SMZL). Subsequent cross-entity comparisons led to the conclusion that stereotyped IG are mostly “disease-specific,” implicating distinct immunopathogenetic processes. Interestingly, mounting evidence suggests that a molecular subclassification of lymphomas based on BcR IG stereotypy is biologically and clinically relevant. Indeed, particularly in CLL, patients assigned to the same subset due to expressing a particular stereotyped BcR IG display remarkably consistent biological background and clinical course, at least for major and well-studied subsets. Thus, the robust assignment to stereotyped subsets may assist in the identification of mechanisms underlying disease onset and progression, while also refining risk stratification. In this book chapter, we provide an overview of the recent BcR IG stereotypy studies in mature B cell malignancies and outline previous and current methodological approaches used for the identification of stereotyped IG.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chiorazzi N, Ferrarini M (2003) B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21:841–894. https://doi.org/10.1146/annurev.immunol.21.120601.141018
Stevenson FK, Sahota SS, Ottensmeier CH et al (2001) The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res 83:81–116
Sutton LA, Agathangelidis A, Belessi C et al (2013) Antigen selection in B-cell lymphomas—tracing the evidence. Semin Cancer Biol 23(6):399–409. https://doi.org/10.1016/j.semcancer.2013.07.006
Dunn-Walters D, Thiede C, Alpen B et al (2001) Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond Ser B Biol Sci 356(1405):73–82. https://doi.org/10.1098/rstb.2000.0751
Ghia P, Granziero L, Chilosi M et al (2002) Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 12(2):149–155. https://doi.org/10.1006/scbi.2001.0423
Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14(8):517–534. https://doi.org/10.1038/nrc3774
Burger JA, Chiorazzi N (2013) B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34(12):592–601. https://doi.org/10.1016/j.it.2013.07.002
Jerkeman M, Hallek M, Dreyling M et al (2017) Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med 282(5):415–428. https://doi.org/10.1111/joim.12600
Fais F, Ghiotto F, Hashimoto S et al (1998) Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102(8):1515–1525. https://doi.org/10.1172/JCI3009
Damle RN, Wasil T, Fais F et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6):1840–1847
Hamblin TJ, Davis Z, Gardiner A et al (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94(6):1848–1854
Ghia P, Stamatopoulos K, Belessi C et al (2007) ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 21(1):1–3. https://doi.org/10.1038/sj.leu.2404457
Langerak AW, Davi F, Ghia P et al (2011) Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases. Leukemia 25(6):979–984. https://doi.org/10.1038/leu.2011.49
Rosenquist R, Ghia P, Hadzidimitriou A et al (2017) Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia 31(7):1477–1481. https://doi.org/10.1038/leu.2017.125
Hallek M, Cheson BD, Catovsky D et al (2018) Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood 131:2745–2760. https://doi.org/10.1182/blood-2017-09-806398
Efremov DG, Ivanovski M, Siljanovski N et al (1996) Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune hemolytic anemia. Blood 87(9):3869–3876
Johnson TA, Rassenti LZ, Kipps TJ (1997) Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 158(1):235–246
Widhopf GF 2nd, Kipps TJ (2001) Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol 166(1):95–102
Tobin G, Thunberg U, Johnson A et al (2003) Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 101(12):4952–4957. https://doi.org/10.1182/blood-2002-11-3485
Ghiotto F, Fais F, Valetto A et al (2004) Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 113(7):1008–1016. https://doi.org/10.1172/JCI19399
Messmer BT, Albesiano E, Efremov DG et al (2004) Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 200(4):519–525. https://doi.org/10.1084/jem.20040544
Tobin G, Thunberg U, Karlsson K et al (2004) Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 104(9):2879–2885. https://doi.org/10.1182/blood-2004-01-0132
Widhopf GF 2nd, Rassenti LZ, Toy TL et al (2004) Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 104(8):2499–2504. https://doi.org/10.1182/blood-2004-03-0818
Stamatopoulos K, Belessi C, Hadzidimitriou A et al (2005) Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 106(10):3575–3583. https://doi.org/10.1182/blood-2005-04-1511
Murray F, Darzentas N, Hadzidimitriou A et al (2008) Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 111(3):1524–1533. https://doi.org/10.1182/blood-2007-07-099564
Bomben R, Dal Bo M, Capello D et al (2009) Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol 144(4):492–506. https://doi.org/10.1111/j.1365-2141.2008.07469.x
Darzentas N, Hadzidimitriou A, Murray F et al (2010) A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia 24(1):125–132. https://doi.org/10.1038/leu.2009.186
Stamatopoulos K, Belessi C, Moreno C et al (2007) Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 109(1):259–270. https://doi.org/10.1182/blood-2006-03-012948
Agathangelidis A, Darzentas N, Hadzidimitriou A et al (2012) Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 119(19):4467–4475. https://doi.org/10.1182/blood-2011-11-393694
Malcikova J, Stalika E, Davis Z et al (2014) The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. Br J Haematol 166(4):621–625. https://doi.org/10.1111/bjh.12893
Navrkalova V, Young E, Baliakas P et al (2016) ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. Haematologica 101(9):e369–e373. https://doi.org/10.3324/haematol.2016.142968
Strefford JC, Sutton LA, Baliakas P et al (2013) Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 27(11):2196–2199. https://doi.org/10.1038/leu.2013.98
Sutton LA, Young E, Baliakas P et al (2016) Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica 101(8):959–967. https://doi.org/10.3324/haematol.2016.141812
Papakonstantinou N, Ntoufa S, Chartomatsidou E et al (2013) Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med 19:115–123. https://doi.org/10.2119/molmed.2013.00005
Kanduri M, Marincevic M, Halldorsdottir AM et al (2012) Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. Epigenetics 7(12):1435–1442. https://doi.org/10.4161/epi.22901
Arvaniti E, Ntoufa S, Papakonstantinou N et al (2011) Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 96(11):1644–1652. https://doi.org/10.3324/haematol.2011.044792
Ntoufa S, Vardi A, Papakonstantinou N et al (2012) Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med 18:1281–1291. https://doi.org/10.2119/molmed.2011.00480
Ntoufa S, Papakonstantinou N, Apollonio B et al (2016) B cell anergy modulated by TLR1/2 and the miR-17 approximately 92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4. J Immunol 196(10):4410–4417. https://doi.org/10.4049/jimmunol.1502297
Minici C, Gounari M, Ubelhart R et al (2017) Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun 8:15746. https://doi.org/10.1038/ncomms15746
Baliakas P, Agathangelidis A, Hadzidimitriou A et al (2015) Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood 125(5):856–859. https://doi.org/10.1182/blood-2014-09-600874
Baliakas P, Hadzidimitriou A, Sutton LA et al (2014) Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol 1(2):e74–e84. https://doi.org/10.1016/S2352-3026(14)00005-2
Del Giudice I, Chiaretti S, Santangelo S et al (2014) Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients’ prognosis. Am J Hematol 89(1):74–82. https://doi.org/10.1002/ajh.23591
Maura F, Cutrona G, Fabris S et al (2011) Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. PLoS One 6(8):e24313. https://doi.org/10.1371/journal.pone.0024313
Rossi D, Spina V, Cerri M et al (2009) Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res 15(13):4415–4422. https://doi.org/10.1158/1078-0432.CCR-08-3266
Xochelli A, Baliakas P, Kavakiotis I et al (2017) Chronic lymphocytic leukemia with mutated IGHV4-34 receptors: shared and distinct immunogenetic features and clinical outcomes. Clin Cancer Res 23(17):5292–5301. https://doi.org/10.1158/1078-0432.CCR-16-3100
Baliakas P, Mattsson M, Hadzidimitriou A et al (2018) No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica 103(4):e158–e161. https://doi.org/10.3324/haematol.2017.182634
Stamatopoulos K, Agathangelidis A, Rosenquist R et al (2017) Antigen receptor stereotypy in chronic lymphocytic leukemia. Leukemia 31(2):282–291. https://doi.org/10.1038/leu.2016.322
Agathangelidis A, Bystry V, Hadzidimitriou A et al (2015) Higher-order immunoglobulin sequence relations for major subsets of chronic lymphocytic leukemia: uniqueness versus equivalence. In: Paper presented at the 20th congress of the European Hematology Association (EHA), Vienna
Camacho FI, Algara P, Rodriguez A et al (2003) Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 101(10):4042–4046. https://doi.org/10.1182/blood-2002-11-3456
Kienle D, Krober A, Katzenberger T et al (2003) VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 102(8):3003–3009. https://doi.org/10.1182/blood-2003-05-1383
Orchard J, Garand R, Davis Z et al (2003) A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101(12):4975–4981. https://doi.org/10.1182/blood-2002-06-1864
Schraders M, Oeschger S, Kluin PM et al (2009) Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. Mod Pathol 22(3):416–425. https://doi.org/10.1038/modpathol.2008.199
Thorselius M, Walsh S, Eriksson I et al (2002) Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol 68(4):217–224
Walsh SH, Thorselius M, Johnson A et al (2003) Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 101(10):4047–4054. https://doi.org/10.1182/blood-2002-11-3479
Hadzidimitriou A, Agathangelidis A, Darzentas N et al (2011) Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 118(11):3088–3095. https://doi.org/10.1182/blood-2011-03-343434
Agathangelidis A, Hadzidimitriou A, Rosenquist R et al (2011) Unlocking the secrets of immunoglobulin receptors in mantle cell lymphoma: implications for the origin and selection of the malignant cells. Semin Cancer Biol 21(5):299–307. https://doi.org/10.1016/j.semcancer.2011.09.009
Xochelli A, Sutton LA, Agathangelidis A et al (2015) Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. Am J Pathol 185(6):1740–1748. https://doi.org/10.1016/j.ajpath.2015.02.006
Pouliou E, Xochelli A, Kanellis G et al (2017) Numerous ontogenetic roads to mantle cell lymphoma: immunogenetic and immunohistochemical evidence. Am J Pathol 187(7):1454–1458. https://doi.org/10.1016/j.ajpath.2017.02.017
Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507–516. https://doi.org/10.1056/NEJMoa1306220
Bikos V, Darzentas N, Hadzidimitriou A et al (2012) Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 26(7):1638–1646. https://doi.org/10.1038/leu.2012.3
Zibellini S, Capello D, Forconi F et al (2010) Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica 95(10):1792–1796. https://doi.org/10.3324/haematol.2010.025437
Kostareli E, Gounari M, Janus A et al (2012) Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia 26(5):1127–1131. https://doi.org/10.1038/leu.2011.311
Xochelli A, Bikos V, Polychronidou E et al (2015) Unique versus common: disease-biased immunoglobulin gene repertoires along with public antigen receptor stereotypes in marginal zone B-cell lymphoproliferations. In: 57th ASH annual meeting, Orlando, FL
Xu JL, Davis MM (2000) Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 13(1):37–45
Barrios Y, Jirholt P, Ohlin M (2004) Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor. J Mol Recognit 17(4):332–338. https://doi.org/10.1002/jmr.679
Brochet X, Lefranc MP, Giudicelli V (2008) IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36(Web Server):W503–W508. https://doi.org/10.1093/nar/gkn316
Henikoff S, Henikoff JG (1993) Performance evaluation of amino acid substitution matrices. Proteins 17(1):49–61. https://doi.org/10.1002/prot.340170108
Rigoutsos I, Floratos A (1998) Combinatorial pattern discovery in biological sequences: the TEIRESIAS algorithm. Bioinformatics 14(1):55–67
Kirkham PM, Mortari F, Newton JA et al (1992) Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding. EMBO J 11(2):603–609
Bystry V, Agathangelidis A, Bikos V et al (2015) ARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy. Bioinformatics 31(23):3844–3846. https://doi.org/10.1093/bioinformatics/btv456
Polychronidou E, Kalamaras I, Agathangelidis A et al (2018) Automated shape-based clustering of 3D immunoglobulin protein structures in chronic lymphocytic leukemia. BMC Bioinformatics 19:414
Langerak AW, Bruggemann M, Davi F et al (2017) High-throughput immunogenetics for clinical and research applications in immunohematology: potential and challenges. J Immunol 198(10):3765–3774. https://doi.org/10.4049/jimmunol.1602050
Acknowledgments
This work was supported in part by H2020 “AEGLE, An analytics framework for integrated and personalized healthcare services in Europe”, by the EU; “MEDGENET, Medical Genomics and Epigenomics Network” (No. 692298) by the EU; “TRANSCAN-179” NOVEL JTC 2016; and “Odysseus” implemented under the Action “Reinforcement of the Research and Innovation Infrastructure,” funded by the Operational Programme “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014–2020) and co-financed by Greece and the European Union (European Regional Development Fund). Andreas Agathangelidis is a recipient of a Fellowship for Postgraduate Research by the Hellenic Foundation for Research and Innovation.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Agathangelidis, A., Psomopoulos, F., Stamatopoulos, K. (2019). Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas. In: Küppers, R. (eds) Lymphoma. Methods in Molecular Biology, vol 1956. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9151-8_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9151-8_7
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9150-1
Online ISBN: 978-1-4939-9151-8
eBook Packages: Springer Protocols